
INSP Stock Forecast & Price Target
INSP Analyst Ratings
Bulls say
Inspire Medical Systems has demonstrated strong growth dynamics, with Q4 revenue reaching $239.7 million, reflecting a 24.5% year-over-year increase, while earnings per share of $1.15 surpassed consensus expectations of $0.73. The company has seen a notable rise in therapy utilization, increasing from 1.1 procedures per month in 2021 to 1.8 in 2024, indicating enhanced adoption of their neurostimulation technology for obstructive sleep apnea. Furthermore, Inspire is well-positioned for future growth, supported by expansion initiatives, increasing procedure efficiencies, and innovative product launches, which collectively suggest significant potential for revenue enhancement and market penetration.
Bears say
Inspire Medical Systems faces a negative outlook due to several concerning factors, including a projected lower earnings per share (EPS) estimate decrease from $2.41 to $2.22 for 2025, despite being above street expectations. The firm's revenue growth appears stagnant, with sales estimates for 2025 of $945 million being only modestly above the previous year's guidance and underperforming compared to management's outlined targets. Additionally, a downside scenario factors in risks related to slower market penetration, reduced patient utilization, delayed pathways to profitability, and potential competition, which could further hinder Inspire's long-term growth prospects.
This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.
INSP Analyst Forecast & Price Prediction
Start investing in INSP
Order type
Buy in
Order amount
Est. shares
0 shares